{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:04Z","timestamp":1790889604453,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03982-2","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:08:09Z","timestamp":1751965689000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-5830","authenticated-orcid":false,"given":"Ana Fern\u00e1ndez","family":"Montes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2093-3316","authenticated-orcid":false,"given":"Ismael Mac\u00edas","family":"Declara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-6871","authenticated-orcid":false,"given":"Nieves Mart\u00ednez","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-2780","authenticated-orcid":false,"given":"Virginia","family":"Arrazubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-1600","authenticated-orcid":false,"given":"Beatriz Garc\u00eda","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-3813","authenticated-orcid":false,"given":"Paula Jim\u00e9nez","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"3982_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3982_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1470-2045(22)00704-5","volume":"24","author":"I Soerjomataram","year":"2023","unstructured":"Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 2023;24:22\u201332.","journal-title":"Lancet Oncol"},{"key":"3982_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.mcna.2019.12.005","volume":"104","author":"M Malec","year":"2020","unstructured":"Malec M, Shega JW. Management of gastrointestinal symptoms (Nausea, Anorexia and Cachexia, Constipation) in advanced illness. Med Clin North Am. 2020;104:439\u201354.","journal-title":"Med Clin North Am"},{"key":"3982_CR4","first-page":"333","volume":"25","author":"D Walsh","year":"2017","unstructured":"Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC\/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333\u201340.","journal-title":"Support Care Cancer"},{"issue":"2","key":"3982_CR5","first-page":"120","volume":"20","author":"DR Fresco","year":"2004","unstructured":"Fresco DR, Su\u00e1rez L. Recomendaciones para la prevenci\u00f3n y el tratamiento de n\u00e1useas y v\u00f3mitos inducidos por quimioterapia. Rev Med Uruguay. 2004;20(2):120\u20139.","journal-title":"Rev Med Uruguay"},{"key":"3982_CR6","first-page":"117","volume":"27","author":"R Vera","year":"2008","unstructured":"Vera R, Mart\u00ednez M, Salgado E, L\u00e1inez N, Illarramendi JJ, Alb\u00edstur JJ. Tratamiento de la emesis inducida por quimioterapia. An Sist Sanit Navar. 2008;27:117\u201323.","journal-title":"An Sist Sanit Navar"},{"key":"3982_CR7","first-page":"253","volume":"34","author":"P Sampedro Domarco","year":"2020","unstructured":"Sampedro Domarco P, Cameselle Garcia S, Garc\u00eda GJ. Prevenci\u00f3n y tratamiento de la emesis en el paciente oncol\u00f3gico. Revisiones en c\u00e1ncer. 2020;34:253\u201365. Accessed 02 Jan 2025.","journal-title":"Revisiones en c\u00e1ncer"},{"key":"3982_CR8","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 8 Dec 2024."},{"key":"3982_CR9","unstructured":"MASCC. Multinational Association of Supportive Care in Cancer (MASCC). https:\/\/mascc.org\/. Accessed 08 Dec 2024."},{"key":"3982_CR10","unstructured":"DeVita VT, Hellman S, Rosenberg SA. (2015) DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles & Practice of Oncology. 10th ed. Wolters Kluwer Health."},{"key":"3982_CR11","unstructured":"Abeloff MD, Armitage JO, Lichter AS, Schiller GJ. Abeloff\u2019s (2014) Clinical Oncology (5th ed.). Philadelphia (PA): Elsevier; 2013."},{"key":"3982_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/B978-0-444-53491-0.00027-4","volume":"117","author":"WL Hasler","year":"2013","unstructured":"Hasler WL. Pathology of emesis: Its autonomic basis. Handb Clin Neurol. 2013;117:337\u201352.","journal-title":"Handb Clin Neurol"},{"key":"3982_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.conb.2020.03.006","volume":"62","author":"CD Yu","year":"2020","unstructured":"Yu CD, Xu QJ, Chang RB. Vagal sensory neurons and gut-brain signaling. Curr Opin Neurobiol. 2020;62:133\u201340.","journal-title":"Curr Opin Neurobiol"},{"key":"3982_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2020.10.014","volume":"54","author":"Z Chen","year":"2021","unstructured":"Chen Z, Luo J, Li J, Kim G, Stewart A, Urban JF, et al. Interleukin-33 promotes serotonin release from enterochromaffin cells for intestinal homeostasis. Immunity. 2021;54:151-163.e6.","journal-title":"Immunity"},{"issue":"4","key":"3982_CR15","doi-asserted-by":"publisher","first-page":"e60537","DOI":"10.1371\/journal.pone.0060537","volume":"8","author":"CC Horn","year":"2013","unstructured":"Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, et al. Why can\u2019t rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS ONE. 2013;8(4):e60537.","journal-title":"PLoS ONE"},{"key":"3982_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1139\/y90-039","volume":"68","author":"INC Lawes","year":"1990","unstructured":"Lawes INC. The origin of the vomiting response: a neuroanatomical hypothesis. Can J Physiol Pharmacol. 1990;68:254\u20139.","journal-title":"Can J Physiol Pharmacol"},{"key":"3982_CR17","unstructured":"Berger MJ, Anand S, Agarwal R, Bagegni NA, Barbour S, Bitar H, et al. (2024) NCCN Guidelines Version 2.2024 Antiemesis Continue [Internet]. https:\/\/www.nccn Accessed 02 Jan 2025."},{"key":"3982_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s12094-022-02802-1","volume":"24","author":"M Majem","year":"2022","unstructured":"Majem M, de Las PR, Virizuela JA, Cabez\u00f3n-Guti\u00e9rrez L, Cruz P, Lopez-Castro R, et al. SEOM clinical guideline emesis (2021). Clin Translat Oncol. 2022;24:712\u201323.","journal-title":"Clin Translat Oncol"},{"key":"3982_CR19","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.1016\/j.annonc.2023.09.1540","volume":"34","author":"J Weng","year":"2023","unstructured":"Weng J, Kinugasa F, Kajikawa S, Yamanaka Y, Ugawa T, Fushiki H, et al. 38P Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets. Ann Oncol. 2023;34:S198.","journal-title":"Ann Oncol"},{"key":"3982_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2024.42.3_suppl.372","volume":"42","author":"K Shitara","year":"2024","unstructured":"Shitara K, Pophale R, Matsangou M, Park JW, Oh M, Bhattacharya PP, et al. Management of nausea and vomiting (N\/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2\u2212, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies. J Clin Oncol. 2024;42:372\u2013372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3982_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/cancers14041022","volume":"14","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, Arpino G, Biganzoli L, Lonardi S, Puglisi F, Santini D, et al. Emetogenicity of Antibody-Drug Conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an italian expert panel. Cancers (Basel). 2022;14(4):1022.","journal-title":"Cancers (Basel)"},{"key":"3982_CR22","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u201397.","journal-title":"J Clin Oncol"},{"key":"3982_CR23","first-page":"1139","volume":"27","author":"D Tsuji","year":"2019","unstructured":"Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2019;27:1139\u201347.","journal-title":"Support Care Cancer"},{"key":"3982_CR24","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.clnu.2022.08.003","volume":"41","author":"D Gala","year":"2022","unstructured":"Gala D, Wright HH, Zigori B, Marshall S, Crichton M. Dietary strategies for chemotherapy-induced nausea and vomiting: a systematic review. Clin Nutr. 2022;41:2147\u201355.","journal-title":"Clin Nutr"},{"key":"3982_CR25","doi-asserted-by":"publisher","first-page":"102939","DOI":"10.1016\/j.critrevonc.2020.102939","volume":"149","author":"A Eliasen","year":"2020","unstructured":"Eliasen A, Dalhoff K, Mathiasen R, Schmiegelow K, Rechnitzer C, Schelde AB, et al. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;149:102939.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3982_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","volume":"21","author":"PB Tremblay","year":"2003","unstructured":"Tremblay PB, Kaiser R, Sezer O, R\u00f6sler N, Schelenz C, Possinger K, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21:2147\u201355.","journal-title":"J Clin Oncol"},{"key":"3982_CR27","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1200\/JCO.2002.09.064","volume":"20","author":"R Kaiser","year":"2002","unstructured":"Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805\u201311.","journal-title":"J Clin Oncol"},{"key":"3982_CR28","first-page":"9","volume":"2024","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2023;2024:9.","journal-title":"ESMO Open"},{"key":"3982_CR29","first-page":"32","volume":"2024","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Celio L, Hesketh P, Zhang L, Navari R, Chan A, et al. updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer. 2023;2024:32.","journal-title":"Support Care Cancer"},{"issue":"1","key":"3982_CR30","first-page":"45","volume":"32","author":"F Scott\u00e9","year":"2024","unstructured":"Scott\u00e9 F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, et al. 2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care Cancer. 2024;32(1):45.","journal-title":"Supportive Care Cancer"},{"key":"3982_CR31","first-page":"32","volume":"2024","author":"I Olver","year":"2023","unstructured":"Olver I, Clark-Snow R, Ruhlmann CH, Garcia-del-Barrio MA, Schwartzberg L, Rapoport BL, et al. updated MASCC\/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer. 2023;2024:32.","journal-title":"Support Care Cancer"},{"key":"3982_CR32","first-page":"32","volume":"2024","author":"SKF Kennedy","year":"2020","unstructured":"Kennedy SKF, Goodall S, Lee SF, DeAngelis C, Jocko A, Charbonneau F, et al. ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2020;2024:32.","journal-title":"Support Care Cancer"},{"key":"3982_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2017","unstructured":"Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2017;22:88\u201395.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"3982_CR34","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, et al. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021;4(4):e215250\u2013e212550.","journal-title":"JAMA Netw Open"},{"key":"3982_CR35","first-page":"32","volume":"2024","author":"CH Ruhlmann","year":"2023","unstructured":"Ruhlmann CH, Jordan K, Jahn F, Maranzano E, Molassiotis A, Dennis K. Updated MASCC\/ESMO consensus recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting. Support Care Cancer. 2023;2024:32.","journal-title":"Support Care Cancer"},{"key":"3982_CR36","first-page":"1","volume":"4","author":"Z-H Wang","year":"2018","unstructured":"Wang Z-H, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018;4:1\u20137.","journal-title":"Chronic Dis Transl Med"},{"key":"3982_CR37","first-page":"32","volume":"2024","author":"BL Rapoport","year":"2023","unstructured":"Rapoport BL, Herrstedt J, Snow RC, Radhakrishnan V, Saito M, Navari RM, et al. updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023;2024:32.","journal-title":"Support Care Cancer"},{"key":"3982_CR38","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.23.02596","volume":"42","author":"IM Braun","year":"2024","unstructured":"Braun IM, Bohlke K, Abrams DI, Anderson H, Balneaves LG, Bar-Sela G, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42:1575\u201393.","journal-title":"J Clin Oncol"},{"key":"3982_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4103\/0366-6999.180530","volume":"129","author":"SB Bian","year":"2016","unstructured":"Bian SB, Shen WS, Xi HQ, Wei B, Chen L. Palliative therapy for gastric outlet obstruction caused by unresectable gastric cancer: a meta-analysis comparison of gastrojejunostomy with endoscopic stenting. Chin Med J (Engl). 2016;129:1113\u201321.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3982_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2012.373","volume":"108","author":"M Camilleri","year":"2013","unstructured":"Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18\u201337.","journal-title":"Am J Gastroenterol"},{"key":"3982_CR41","first-page":"32","volume":"2024","author":"A Molassiotis","year":"2023","unstructured":"Molassiotis A, Lou AM, Fleury M, Olver I, Giusti R, Scotte F. MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Support Care Cancer. 2023;2024:32.","journal-title":"Support Care Cancer"},{"key":"3982_CR42","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.cgh.2021.03.046","volume":"19","author":"O Ahmed","year":"2021","unstructured":"Ahmed O, Lee JH, Thompson CC, Faulx A. AGA clinical practice update on the optimal management of the malignant alimentary tract obstruction: expert review. Clin Gastroenterol Hepatol. 2021;19:1780\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3982_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100131","volume":"7","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Pazo-Cid RA, Lonardi S, Swanson L, Arango MJ, Enzinger P, et al. Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND\/UCLA modified Delphi panel study. ESMO Gastrointest Oncol. 2025;7: 100131.","journal-title":"ESMO Gastrointest Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03982-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:01:54Z","timestamp":1768089714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03982-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3982"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03982-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AFM: receives honoraria for speaker\u2019s bureau participation and serving on advisory boards form Amgen, Servier, Merck, Roche, Astellas, Daichi, Lilly, Astra Zeneca, Merck Sarp &Dome (MSD) and Bristol-Myers Squibb (BMS). Payments of travels and congress registration for Astra Zeneca, Daichi and Roche. IMD: receives honoraria for speaker\u2019s bureau participation, and serving on advisory boards from AMGEN, AstraZeneca, Bristol-Meyers Squibb (BMS), Merck Sharp & Dohme (MSD), Lilly and Sanofi. Payment of travels and congress registration fees from AMGEN, Merck Sharp & Dohme (MSD), Merck KGaA, Bristol-Meyers Squibb (BMS), AstraZeneca, IPSEN and ADVANZ PHARMA SPAIN, S.L.U. NML: receives honoraria for speaker\u2019s bureau participation and serving on advisory boards from AAA (a Novartis company), AMGEN, AstraZeneca, Bristol-Meyers Squibb (BMS), Merck Sharp & Dohme (MSD), Servier, Takeda. Payment of travels and congress registration fees from AAA (a Novartis company), ADVANZ PHARMA SPAIN, S.L.U. AMGEN, Merck Sharp & Dohme (MSD), Roche and Servier. VA: receives honoraria for speaker\u2019s bureau participation and serving on advisory boards form Lilly. Beigene, Organon, Astellas, Merck Sarp &Dome (MSD) and Bristol-Myers Squibb (BMS). Payments of travels and congress registration for Merck and MSD. BGP: receives honoraria for speakers'bureau participation and serving on advisory boards from Amgen, AAA (a Novartis company), Servier, Roche Farma, Lilly. Novartis, Eisai, Merck Sharp & Dohme (MSD) and Bristol-Myers Squibb (BMS). Payment of travels and congress registration fees from Servier, Novartis, Merck, Roche Farma, Ipsen, Lilly, Merck Sharp & Dohme (MSD), Amgen and Bristol-Myers Squibb (BMS). PJF: receives honoraria for speakers'bureau participation, and serving on advisory boards from Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Servier, Takeda, and Viatri and research grants from Astellas, AstraZeneca, BMS, and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}